Detalhe da pesquisa
1.
CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase.
Nucleic Acids Res
; 51(D1): D1230-D1241, 2023 01 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36373660
2.
Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms.
Mod Pathol
; 37(2): 100397, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38043791
3.
TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia.
Blood
; 140(1): 58-72, 2022 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35390143
4.
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.
Blood
; 140(16): 1753-1763, 2022 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35512188
5.
A framework for the clinical implementation of optical genome mapping in hematologic malignancies.
Am J Hematol
; 99(4): 642-661, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38164980
6.
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Cancer
; 129(4): 560-568, 2023 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36458426
7.
Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.
Br J Haematol
; 203(4): 581-592, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37608562
8.
Genome Mapping Nomenclature.
Cytogenet Genome Res
; 2023 Dec 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38071973
9.
ROS1 Alterations as a Potential Driver of Gliomas in Infant, Pediatric, and Adult Patients.
Mod Pathol
; 36(11): 100294, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37532182
10.
Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2).
Haematologica
; 108(9): 2331-2342, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36951163
11.
The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors.
Am J Hematol
; 98(4): 658-665, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36683287
12.
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era.
Am J Hematol
; 98(10): 1619-1626, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37485584
13.
Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure.
Am J Hematol
; 98(10): E281-E284, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37515433
14.
Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.
Am J Hematol
; 98(8): 1196-1203, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37183966
15.
Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.
Am J Hematol
; 98(11): 1711-1720, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37635400
16.
Diagnostic work-up of hematological malignancies with underlying germline predisposition disorders (GPD).
Semin Diagn Pathol
; 40(6): 443-456, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37977953
17.
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
Lancet Oncol
; 23(3): 406-415, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35074072
18.
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
N Engl J Med
; 380(22): 2095-2103, 2019 05 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31141631
19.
Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations.
Mod Pathol
; 35(11): 1677-1683, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35690645
20.
Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes.
Mod Pathol
; 35(9): 1212-1219, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35504958